Search the Newsreel

Exelixis Inc (EXEL) Dividends & Stock Splits: Historical Payouts and Event Timeline

This article from TradingKey provides an overview of Exelixis Inc (EXEL)'s dividend and stock split history. It notes that over the past five years, a total of $0.00 USD has been distributed in dividends, indicating no dividend payments have been made during this period. …

Exelixis, Inc. Revenue Breakdown – BX:EX9

The article provides a revenue breakdown for Exelixis, Inc. (BX:EX9), highlighting that the company generated 1.84 billion CHF in its last fiscal year from its top segment, "Medicines for Difficult-to-treat Cancers." The United States was the greatest contributor to this revenue, accounting for 1.70 …

Exelixis Inc (EXEL) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

This article provides a detailed revenue breakdown for Exelixis Inc (EXEL), categorizing it by business segments and geographical regions. CABOMETYX is highlighted as the dominant revenue source, contributing over 91% of the total, followed by license revenues. The United States accounts for the vast …

Exelixis Inc (EXEL) Shareholder Structure: Major Shareholders & Institutional Holdings

This article provides an overview of Exelixis Inc (EXEL) shareholder structure, detailing major institutional holdings and shareholder types. It lists top shareholders like BlackRock and Farallon Capital, their proportion of shares, and changes in their holdings over time. The document also includes a historical …

Elixinol Wellness Ltd Revenue Breakdown – ASX:EXL

EXEL|Exelixis Inc|Price:55.370|Chg%:-0.280

Exelixis Inc (EXEL) is an oncology company with strong fundamentals and high growth potential, though its stock performance has been average over the past month. The company's valuation is considered fair, and it has a high institutional ownership. Analysts generally rate EXEL as a …

Yixin Group Ltd. Revenue Breakdown – HKEX:2858

EXEL Maintained by Morgan Stanley -- Price Target Raised to $53

Morgan Stanley has maintained an Equal-Weight rating on Exelixis (EXEL) while raising its price target from $50.00 to $53.00, an increase of 6%. Despite this cautious optimism, GuruFocus assesses EXEL as 29.1% overvalued with a GF Value™ of $42.86 against its current price of …

Exelixis to Release Second Quarter 2026 Financial Results on Wednesday, August 5, 2026

Exelixis, Inc. announced that it will release its second quarter 2026 financial results on Wednesday, August 5, 2026, after market close. The company will also host a conference call and webcast at 5:00 p.m. ET / 2:00 p.m. PT to discuss these results and …

Exelixis sets Aug. 5 webcast to discuss Q2 results and update

Exelixis (EXEL) Earnings Expected to Grow: Should You Buy?

Exelixis (EXEL) is expected to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended June 2026. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual results compare to …

(EXEL) Movement as an Input in Quant Signal Sets

This article analyzes Exelixis Inc. (NASDAQ: EXEL) using quantitative signals and AI models. It identifies weak near-term sentiment but potential for shifts in the mid and long-term outlook, highlighting no resistance levels above the current price. The analysis provides three distinct trading strategies (Position …

What's Driving Exelixis' Recent Momentum and 2026 Outlook

Exelixis is experiencing strong growth driven by its flagship drug Cabometyx, which recently received label expansion into neuroendocrine tumors. The company's next-generation TKI, zanzalintinib, is a critical future asset with potential FDA approval in metastatic colorectal cancer by December 2026 and promising Phase 3 …

Will Exelixis (EXEL) Beat Estimates Again in Its Next Earnings Report?

Is Exelixis (EXEL) Undervalued Or Already Priced In On Its Oncology Growth Story?

Elixinol Wellness (ASX:EXL): Can This Wellness Stock Recover After a Tough Run?

Exelixis closes 0.7% below its high as volume improves, while biotech momentum runs hotter

EXEL added 5.5% for the week on 18.2M shares, keeping its 13-week Trend Signal active, but the move comes with valuation distance and a neutral expectancy read.

Exelixis (EXEL) Up 6% Since Last Earnings Report: Can It Continue?

Elixinol Wellness (ASX: EXL) Soars on Priceline Distribution Deal

Elixir Energy (ASX:EXR) Advances Flow Testing at Pipeline-Adjacent Queensland Well

Why Exelixis (EXEL) Is Up 9.0% After Strong Q1 2026 Earnings And New Buyback Program

EXEL Q1 Earnings Top Estimates, Colorectal Cancer Drug in Focus

Exelixis Announces First Quarter 2026 Financial Results and Provides Corporate Update

Exelixis (EXEL) Tops Q1 Earnings Estimates

Elixirr posts record revenue and profit after year of expansion

Elixinol Wellness (ASX:EXL) Jumps 14%: What’s Driving the Move?

Earnings call transcript: Elixirr’s robust FY 2025 performance boosts stock

Elixirr International (ELIX) Earnings Date and Reports 2026 $ELIX

Why are Elixirr International FTSE350 shares rising after earnings?

Elixirr International rides AI boom to double-digit growth

Elixir Energy Ltd Gas Project Partnership Advances Commercialisation Strategy

Why did Elixir Energy (ASX:EXR) Gain Momentum Today?

Elixinol Wellness (ASX:EXL) at Rock Bottom: Turnaround Potential or Structural Decline?

Elixir Energy Limited (OTC: ELXPF) Stock Price, News & Analysis

EXEL Q4 Earnings and Revenues Beat, Colorectal Cancer Drug in Focus

Exelixis Announces Fourth Quarter and Fiscal Year 2025 Financial Results and Provides Corporate Update